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Abstract
Background: Developing safe and effective cancer vaccine formulations is a primary focus in the field of cancer
immunotherapy. Dendritic cells (DC) are currently employed as cellular vaccine in clinical trials of tumor immunotherapy.
Recognizing the critical role of DCs in initiating anti-tumor immunity has resulted in the development of several strategies
that target vaccine antigens to DCs to trigger anti-tumor T cell responses. To increase the efficiency of antigen
delivery systems for anti-tumor vaccines, encapsulation of tumor-associated antigens in polymer nanoparticles
(NPs) has been established.
Methods: In this study, the effect of tumor lysate antigen obtained from three stage III breast cancer tissues
encapsulated within PLGA NPs to enhance the DC maturation was investigated. The T-cell immune response
activation was then fallowed up. Fresh breast tumors were initially used to generate tumor lysate antigens
containing poly lactic-co-glycolic acid (PLGA) NP. The encapsulation efficiency and release kinetics were profiled.
The efficiency of encapsulation was measured using Bradford protein assays measuring the dissolved NPs. The
stability of released antigen from NPs was verified using SDS-PAGE. To evaluate the hypothesis that NPs enhances
antigen presentation, including soluble tumor lysate, tumor lysate containing NPs and control NPs the efficiency
of NP-mediated tumor lysate delivery to DCs was evaluated by assessing CD3+ T-cell stimulation after T cell/and
DCs co-culture.
Results: The rate of encapsulation was increased by enhancing the antigen concentration of tumor lysate. However,
increasing the antigen concentration diminished the encapsulation efficiency. In addition, higher initial protein
contenting NPs led to a greater cumulative release. All three patients released variable amounts of IFN-γ, IL-10,
IL-12 and IL-4 in response to re-stimulation. T cells stimulated with lysate-pulsed DCs induced a substantial
increase in IFN-γ and IL-12 production. We demonstrated that NPs containing tumor lysate can induce maturation and
activation of DCs, as antigen alone does.
Conclusion: PLGA-NPs are attractive vehicles for protein antigen delivery which effectively induce stimulation and
maturation of DCs, allowing not only an enhanced antigen processing and immunogenicity or improved antigen
stability, but also the targeted delivery and slow release of antigens.
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Background
Breast cancer is the most common malignant tumor and
the first leading cause of cancer-related deaths in women
worldwide [1]. Although, several methods including sur-
gery, radiotherapy, hormone replacement therapy and
chemotherapy have been used to treat breast cancer, an
effective treatment for patients with metastatic and inva-
sive breast cancer is yet to be established. Cancer immuno-
therapy and vaccines are new therapeutic approaches
which offer a promising treatment against cancer with
minimum adverse effects [2, 3]. Cell-mediated immune
mechanisms have been determined in breast cancers [4].
These immune responses are induced by breast tumor cells
and thus lead to a systemic anti-tumor immunity and re-
gression of breast cancer [5, 6]. Therefore, immunotherapy
may be effective in treating patients with breast cancer.
This kind of therapy concentrates on the induction and
enhancement of immune responses against tumors. In a
limited number of malignancies in which tumor-associated
antigens have been determined, antitumor vaccine strate-
gies have proven to be partially effective, predominantly
based on the loading of professional antigen-presenting
cells (APCs), including DCs [7]. APCs are a group of cells
that can process antigens of both endogenous (normal cell
proteins, tumor or viral antigens) and exogenous origin
(extracellular antigens) [8, 9]. Using DCs which are the
most potent APCs with the unique capability to induce pri-
mary immune responses against tumor-associated antigens
in cancer treatment is a promising approach [10, 11]. In
addition, vaccines act through DCs that induce, regulate
and maintain T-cell immunity [12]. Ex-vivo loaded DC-
based cancer vaccines study has been shown that this
strategy is safe, well tolerated and capable of inducing cel-
lular immune responses [13]. DCs and macrophages are
highly phagocytic cells, capable of taking up any particles
with similar dimensions to the pathogens (up to 10 μm).
Therefore, both large “micro-” and small “nano-” particles
can efficiently be taken up by both cell types [14].
In clinical medicines, NPs have attracted increasing
attention as carriers of therapeutic and/or diagnostic
agents [15]. Generally, cellular uptake of NPs is relatively
higher than that of microparticles. NPs can entrap a
wide range of biologically active compounds varying in
their therapeutic indications, such as hormones, antibi-
otics and anti-cancer drugs [15]. In the recent years, bio-
degradable polymers, such as Poly (D,L-lactic-co-glycolic
acid) (PLGA), have been studied for the fabrication of
drug delivery systems and administration of vaccine
antigens. PLGA is a FDA approved biodegradable poly-
mer [16] that have been widely used in production of
biodegradable surgical sutures and the sustained delivery
of drugs into humans [17, 18]. In this study, the effect of
breast tumor lysate antigen encapsulated within PLGA
NPs to enhance DC maturation and antigen-loaded
mature DC stimulated T-cell immune responses against
breast cancer have been investigated.
Methods
Tumor lysate preparation
Fresh breast tumor was removed from surgical tissues from
three breast cancer patients, washed twice in RPMI-1640
(Invitrogen, USA) and dissected into 1–2 mm3 pieces
under sterile condition. The dissected tissues were incu-
bated overnight at 37 °C in 5 % CO2in enzymatic culture
medium containing DNase, Hyaloronidase and Collage-
nease III (1 mg/ml, 0.1 mg/ml and 1 mg/ml, respectively)
(Sigma-Aldrich, USA) in order to remove the connective
tissue. To remove the undigested connective tissues and
cell debris, the resultant cell suspension was centrifuged for
5 min at 200 × g and the supernatant was discarded. The
cell pallet was washed twice using RPMI 1640 (Sigma-Al-
drich, USA) and was resuspended in 1 ml RPMI 1640.
Tumor cell lysate was prepared by subjecting the cell sus-
pension to four freeze-thaw cycles (alternating liquid nitro-
gen and 37 °C water bath treatment) followed by two steps
of centrifugation at 300 × g for 5 min at 4 °C and then
15,000 rpmfor30 min at 4 °C. The protein concentra-
tion of the lysate was measured as described previously
[19], the supernatant was then collected and passed
through a 0.22 μm filter and stored at −80 °C until use.
Nanoparticle fabrication
PLGA NPs (Sigma-Aldrich, USA) were fabricated using
the solvent evaporation method from a water/oil/water
(W2/O/W1) emulsion as described elsewhere [20]. Briefly,
PLGA composition (50 % glycolide: 50 % lactide) with in-
herent viscosity of 0.39 dL/g (Sigma-Aldrich, USA) were
dissolved in 2 ml dicholoromethane (DCM) (Sigma-
Aldrich, USA). To encapsulate tumor antigen and form a
water-in-oil (O/W1) emulsion, three distinct concentra-
tions (15.39, 19.65, 25.86 μg/ml) of the protein solution in
PBS (signed as Nanoparticle 1–3) was added to 50 μl of
organic solution. The emulsion was then sonicated three
times for 50s (Soniprep, UK) on ice at a 20 % amplitude.
The first emulsion was then made up at three concentra-
tions of 0.5 %, 3 and 5 % by being added drop wise into a
20 ml solution of poly vinyl alcohol (PVA) (Sigma-Aldrich,
USA) in a glass test tube and sonicated simultaneously.
After sonication, thesecond emulsion, W2/O/W1 emul-
sion, was poured into a beaker containing 50 ml of 0.25 %
PVA followed by sonication for 10 s. To eliminate organic
solvent, the second emulsion was then stirred at 500 rpm
and kept under laminar air flow hood overnight. The NP
slurry was then centrifuged at 16,000 rpm for 40 min to
be sedimented. The NPs were then washed three succes-
sive times with 10 ml of distilled water to remove unen-
trapped peptides, residual PVA surfactant and large
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particles. Finally, resultant NPs were resuspended in 5 ml
of water and frozen at −20 °C before being lyophilized.
Nanoparticle characterization
Scanning electron microscopy (SEM) was employed to
characterize NPs in terms of size and morphology. A thin
film of test samples was deposited onto a metal stub with
double-sided adhesive carbon tape (Nisshin EM. Co. Ltd.,
Tokyo, Japan) and coated with a thin layer of gold for
visualization by SEM. Images were collected at three mag-
nifications (20,000, 10,000 and 4000) and analyzed with
the DigXY program; a representative sampling of NP
diameters was recorded and analyzed for each treatment.
Encapsulation efficiency measurement
To determine the encapsulation efficiency, 5 mg of
lyophilized NP was dissolved in 500 μl of DCM (Sigma-
Aldrich, USA) to degrade the NPs. After degradation,
100 μl PBS was gently added to the solution and vor-
texed three times, each time for 10 s, to increase the
contact surface between hydrophilic materials including
PBS and peptides. Supernatant of the samples were col-
lected and analyzed for total protein concentration using
Bradford assay (Biometer, Germany). The bovine serum
albumin (BSA) concentrations used as the standard
ranged between 0.5 and 250 μg/ml. Finally, the encapsu-
lation efficiency was calculated using the following
formula as described by Prasad et al. [21]:
Protein released=total protein content of NPs  100
Release rate measurement
The rate of protein release from NPs was measured under
controlled condition. Five milligrams of NPs were dis-
persed in 500 μl PBS, pH 7.4, and the suspension was in-
cubated at 37 °C with continuous agitation in an orbital
shaker (200 rpm/min). Periodically, the suspension was
centrifuged at 15,000 × g for 5 min to pellet the spheres.
Supernatants were then collected and stored at −20 °C for
later analysis. The spheres were serially resuspended in
500 μl of fresh PBS in the original tube for further incuba-
tion. The concentration of the released protein was mea-
sured using Bradford assay, applying BSA as the standard.
The cumulative release was studied for 7 days and the re-
lease efficiency was calculated as follow:
Released protein= total protein content of NPs  100
Estimating protein composition and integrity
To determine whether a representative selection of tumor-
associated proteins have been encapsulated and released,
protein composition before and after encapsulation were
compared on the 10 % gradient SDS-PAGE by Silver
Xpress staining kit (Invitrogen, USA).
Dendritic cell generation
Dendritic cells were generated from human peripheral
blood mononuclear cells (PBMCs). Whole blood of each
patient with breast cancer was collected in separate
heparin-containing 50 ml conical tubes and diluted 1:1 in
sterile PBS, layered on ficoll/Hypaque (lymphodex,
Germany) solution, and centrifuged at 1000 g for 30 min at
25 °C. In order to deplete the platelets, the cells were col-
lected and washed with RPMI 1640 (Sigma-Aldrich, USA)
twice and PBMCs were cultured in RPMI-1640 supple-
mented with heat-inactivated filter-sterilized 10 % (v/v)
human AB+ serum, 100U/ml penicillin, and 100 μg/ml
streptomycin (Sigma-Aldrich, USA) with seeding density of
2 × 106cell/ml. The cultured cells were then incubated for
2 h at 37 °C and 5 % CO2 to provide the condition for
adhering the monocytes. Non-adherent cells were
then removed, adherent cells were kept in RPMI-
1640 (Sigma-Aldrich, USA) containing 1000U/ml
granulocyte-macrophage colony-stimulating factor
(GM-CSF) (Sandoz Basel, Switzerland) and 800U/ml
IL-4 (Peprotech, Germany). The culture medium was
changed on days 3, 5 and 6. On day 3, the same
amount of cytokines was added to the culture medium
and immature DCs were then pulsed with NPs, tumor
lysate and tumor lysate loaded NPs (NP-tumor lysate)
0.2 mg per 1 × 106 cells, and were incubated for further
24 h. On day 5, the same volume of culture media was
substituted by monocyte conditioned medium (MCM)
(25%V/V) and 20 ng/ml TNF-α (eBioscience, USA) was
added as maturation factors; the DCs were harvested
after 48 h and subjected to immunophenotyping. The
supernatant was collected and stored at −20 C for IL-
10 and IL-12 cytokines analysis.
Immunophenotyping of monocyte-derived DCs
Immunophenotyping of monocyte-derived DCs was per-
formed by direct immunofluorescence staining of cell sur-
face markers using FITC-labeled anti-CD14, CD83, HLA-
DR, CD86, CD80 and the appropriate isotype controls
(Serotech, UK). Samples were analyzed on FACScanCali-
bur (Becton Dickinson, USA) using Cell Quest software.
T cell proliferation assay
The efficiency of NP-mediated tumor lysate delivery into
DCs was established by assessing CD3+ T-cell stimulation
after co-culturing autologous T cells and DCs. CD3+ T
cells were purified positively from PBMCs by anti CD3
microbead according to manufacturer’s protocol (Miltenyi,
Germany). The purity of T cells was more than 90 %,
which was determined by monoclonal anti-CD3 antibody
staining. Isolated T cells were co-cultured with antigen
Iranpour et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:168 Page 3 of 11
loaded DCs, in 200 μl complete medium (RPMI 1640 sup-
plemented with 10 % AB serum, 1 % HEPES, 100 U/ml
penicillin and 100 μg/ml streptomycin) at a seeding
density of 4 × 105 cells per well in 96-well flat bottom
microtiter plate. The DC:T ratio was1:5, 1:10, 1:20. The
cultured cells were incubated for 5 days at 37 °C in 5 %
CO2. Phytohemagglutinin (PHA) stimulated T cells (2.5 %)
(Sigma-Aldrich, Germany) and DC or T cells alone were
used as positive and negative controls, respectively. T
cell proliferation rate was measured using the 3-(4, 5-
dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. The assay reflected the activity of mito-
chondrial dehydrogenase that transforms light yellow
MTT into dark blue formazan. 20 μl of 5 mg/ml MTT
solution was added into each well for 5 day coculture
of T: DC and the plates were then incubated at 37 °C
for 4 h in a 5 % CO2supplied incubator. The culture
medium was removed and the formazan crystals were
dissolved in Dimethyl sulfoxide (DMSO). The absorb-
ance of formazan solution was measured at 570 nm
using an ELISA reader (Awerness, USA), and prolifera-
tion index was measured as follow:
Proliferation Index ¼ Sample ODð Þ – Blank ODð Þ
Control ODð Þ – Blank ODð Þ
Cytokine release assay
Finally, IL-10 and IL-12 cytokine released into super-
natant of mature DCs and IFN-ϒ and IL-4 content of
the stimulated T cell supernatants were analyzed using
commercially available ELISA kits (Peprotech, USA).
Statistical analysis
Statistical analysis was done using SPSS version 17.0
(SPSS, Surrey UK). Mann–Whitney U and Kruskal-
Wallis tests were used to compare cytokine production
by DC and T cells under different conditions. The data
depicted in each figure corresponds to one representa-
tive experiment of at least three independently per-
formed experiments. A level of ≤ 0.05 was deemed to be
statistically significant.
Results
Encapsulation efficacy and release measurement
Encapsulation efficiency (EE) of the tumor lysate into
NPs was measured by calculating the ratio of the re-
leased proteins to the initial amount of tumor extract, as
explained in method section. The rate of encapsulation
was increased with enhancing the protein concentration
of tumor lysate which resulted in a decrease in the en-
capsulation efficacy (Table 1). Over a 7-day period, ap-
proximate functional life span of an Ag-loaded DC,
cumulative release of NP was measured during incuba-
tion of NP phosphate buffered saline to estimate the
total amount of Ag delivered from NPs. Biphasic protein
release, “burst of protein release”, was observed over the
first 24–48 h and a further sustained release was not ob-
served over the period of the subsequent days (Fig. 1). In
Table 1 Effect of 3 different concentration of tumor- derived lysate on encapsulation rate and encapsulation efficiency










Nanoparticle1 15.39 50 12.31 50 79.9
Nanoparticle2 19.65 50 16.4 50 83.46




























Fig. 1 Comparison of cumulative protein release from nanoparticles fabricated from freshly isolated human breast cancer tumor lysates. The amount
of protein released from nanoparticle 1–3 was 9.93 μg/mg, 13.40 μg/mg and 15.66 μg/mg, respectively
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addition, higher initial protein content in the NPs led to
a greater cumulative release (Table 2).
Conservation of the entrapped antigen integrity
To verify the possible changes in tumor-associated
protein contents during encapsulation process pre-
and post-encapsulation samples were subjected to
electrophoretic analysis on SDS-PAGE gels followed
by silver-staining. A relative paucity of bands between
10 and 70 kDa was noted in NP released samples
with silver-stained SDS-PAGE gel (Fig. 2a). Pre and
post encapsulation protein release indicated and
uniform molecular weight and bands during over
7 days or an approximate functional life span of an
Ag-loaded DC (Fig. 2b).
Morphology and size
To measure the morphology and the size of the antigen
loaded NPs, three different concentrations of PVA were
used as a stabilizer (0.5, 3 and 5 %). Scanning electron
microscopy was used to compare morphological appear-
ances of the NPs derived from soluble lysates. All NP
preparations were spherical with a wide size distribution.
The smallest range of NPs was detected in the highest
concentration of PVA (Fig. 3).
Biological activity of encapsulated antigen
To determine the effectiveness of NP mediated antigen
delivery, a series of experiments were performed using
monocyte-derived DCs and peripheral blood CD3+ T
cells. The efficiency and rate of encapsulation were
evaluated in three concentrations, including 15, 20,
and 25 μg/ml of tumor lysate. The data showed that
the efficiency and rate of encapsulation at inter-
mediate concentration (20 μg/ml) of NPs were at
their highest. Tumor lysate with concentration of
120μg/ml without any PLGA and NPs alone were
used as control (Fig. 4).
Immunophenotyping of DCs
Flow cytometric analysis of DCs treated with three dif-
ferent manufactured antigen loaded NPs compared to
either tumor lysate or NPs alone showed thatNP3
pulsed DCs expressed upper levels of, HLA-DR and
lower levels of CD14 and CD86markers significantly
(P ≤ 0.05), while expression of CD83 and CD80
markers were significantly up and down-regulated re-
spectively (P ≤ 0.05). Furthermore, the data of this
study showed that the tumor lysate loaded NPs trig-
gers a more efficient maturation of monocyte-derived
DCs compared to either tumor lysate or NPs alone
(P ≤ 0.05) (Figs. 5 and 6).
T cell proliferation
CD3+ T-cell populations were isolated by magnetic
cell sorting (MACS); DCs were generated from per-
ipheral blood using granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-4. Loaded DCs
were used to stimulate autologous CD3+ T cells in
the standard co-culture experiments. After 5 days of
interaction, supernatants of co-incubated DCs and
CD3+ T cells were collected and analyzed for cyto-
kine production and MTT assay was used to measure
Table 2 Effect of poly lactic-co-glycolic acid (PLGA) protein
content on release rate







Fig. 2 Silver-stained SDS–PAGE analysis of tumor lysates in PLGA nanoparticle supernatant before and after encapsulation. a Proteins contents of
tumor lysates before and after encapsulation from three patients (n = 3), b Protein contents of tumor lysate before encapsulation (pre) and seven
successive days after encapsulation (post 1–7), L: protein ladder
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stimulation index and NP-mediated antigen delivery
induced T cell proliferation, in three kinds of fabri-
cated NPs and respective ratios for all three patients.
Although, proliferation rate and stimulation index
varied from patient to patient, however NP3 showed
highest proliferation indices in all three patients. The
highest proliferation rate was detected in 1:10 ratio of
DCs and T cells (Fig. 7a). Furthermore, in comparison
to the control groups (tumor lysate and NP alone)
higher T cell stimulation was observed in the tumor
antigen loaded NP3 nonsignificantly (Fig. 7b).
Cytokine release
IL-12 and IL-10 cytokine profile of mature DCs was ana-
lyzed in the supernatant of seventh day DC culture using
a commercially available sandwich ELISA. In compari-
son to tumor lysate alone, tumor antigen loaded NP
pulsed DCs substantially released more IL-12 and IL-10
cytokines, moreover, our findings also revealed that the
level of secreted IL-12 was higher than of IL-10 signifi-
cantly (P ≤ 0.05) (Fig. 8a, b).
Encapsulated lysate pulsed DCs stimulated T cells of
all three patients released variable amounts of IFN-γ and
Fig. 3 Scanning electron micrograph of PLGA 50:50, 75KDa manufactured with various concentrations of PVA; a 0.5 % PVA, b 3 % PVA and c 5 %
PVA. NPs formed with higher concentration of PVA were smaller than those made using lower concentration of PVA (Mean ± SD: 232 ± 0.62 nm
vs. 1062 ± 4.65 nm)
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IL-4, compared to tumor lysate alone, stimulation of T
cells with NP-lysate-pulsed DCs induced a nonsignifi-
cant increase in IFN-γ and IL-4secretions (Fig. 9a, b).
Discussion
In the present study, the effect of PLGA NPs in deliv-
ery of tumor antigen to DCs has been evaluated. A
wide variety of NPs have been developed and
employed as delivery vehicles in the form of micro or
nanoparticles. PLGA as a biodegradable particle have
been successfully used as vehicles for antigen delivery
[20]. NPs enhance not only the immunogenicity and
stability, but also the targeted delivery and slow re-
lease of antigens. DCs as specialized APCs are cur-
rently of particular interest in cancer immunotherapy.
However, there are a few studies have been carried out
to evaluate encapsulation of the tumor lysate derived
from solid-organ malignancies within PLGA spheres
in humans [21]. Encapsulation and delivery of an anti-
gen mixture derived from breast cancer in human has
not yet been reported. The aims of investigating the
encapsulation techniques for tumor lysates in murine
and human models are to enhance the delivery of
tumor associated proteins into the microenvironment of
DC maturation and graduate release of antigens within
the approximate period of DC functional maturation or
life span [20, 21]. The findings of the present study
showed that increase in concentration of tumor lysate led
to an increment in the rate of encapsulation or protein en-
trapment. In contrast, the encapsulation efficiency was de-
creased at higher concentrations of tumor lysate. This
reduction in encapsulation efficiency is likely due to the
higher protein concentration gradient from the inner to
the outer aqueous phase [22]. This pattern of encapsula-
tion has been also reported by some other studies [21, 23].
The data in the present study illustrated that the optimal
concentration of NPs to achieve the best efficiency and
rate of encapsulation was the intermediate concentration;
(20 μg/ml). This concentration of polymer might enhance
the protein encapsulation as the result of faster solidifica-
tion of the particles. Antigen cross-presentation to CD8
+Tcells was found to be low, when delivered in soluble
form. However, encapsulation within PLGA NPs increased
cellular uptake of soluble antigen and led to a 1000-fold
increase in T-cell mediated immunostimulatory cytokine
secretion compared to the antigen-free loafing. It has been
also demonstrated in this study that the higher concentra-
tion of initial protein loaded in the NPs produced a greater
Fig. 4 Phagocytosis of tumor antigen pulsed nanoparticles by immature dendritic cells; a immature dendritic cells on day 4, b immature dendritic
cells treated with nanoparticles, c and d nanoparticles associated with the cells and internalized (black arrows)
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burst release. Furthermore, it has been shown that particle
porosity of PLGA is increased by higher concentration of
initial loaded tumor lysate, which facilitates diffusion of
proteins and leads to a faster release of proteins [22]. It
has been reported that the rate of protein release increases
with an increment in protein or antigen content of the
NPs at a constant polymer molecular weight. The fast
release rate is attributed to the higher concentration gradi-
ent between the antigen-rich NPs and the outer water
phase [24]. Based on the results of this study, burst of pro-
tein release was observed over the first 24–48 h and a fur-
ther sustained release was not observed over the period of
the subsequent days. This could be due to the increased
encapsulation and release of higher molecular weight
Fig. 5 Representative chart of flow cytometric analysis of monocyte-derived DCs. DCs were harvested on day 7 and analyzed by flow cytometry
using monoclonal anti-CD14, HLA-DR, CD80, CD86 and CD83 antibodies and respective isotype controls. Flow cytometric analysis of DCs treated
with NP-containing antigen showed that expression of CD80, CD86, HLADR, CD83 was up-regulated, while expression of CD14 surface marker
was down-regulated in comparison to DCs pulsed with tumor lysate alone (P ≤ 0.05) Depicted data are averaged from three independent
samples obtained from breast cancer patient (n = 3) (*: indicates the statistical significance)
Fig. 6 Immunophenotyping of monocyte derived dendritic cells pulsed with either tumor lysate or tumor lysate containing nanoparticles, a DCs
treated with tumor antigen pulsed nanoparticles fabricated using three different amounts (concentrations) of PVA, Our results showed that NP3
pulsed DCs expressed upper levels of, HLA-DR and lower levels of CD14 and CD86 markers significantly (P≤ 0.05), while expression of CD83 and
CD80 markers were significantly up and down-regulated respectively (P ≤ 0.05). b Comparison of DCs pulsed with nanoparticle containing tumor
antigen with those pulsed with either tumor lysate or NPs alone, the data of this study showed that the tumor lysate loaded NPs triggers a more
efficient maturation of monocyte-derived DCs compared to either tumor lysate or NPs alone (P ≤ 0.05) Depicted data are averaged from three
independent samples obtained from breast cancer patients (n = 3) (*: indicates the statistical significance)
Iranpour et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:168 Page 8 of 11
proteins. The biphasic release pattern, in which a short
burst is followed by a period of linear release, may be par-
ticularly useful in antigen delivery to DCs [20], since it
provides a continuous supply of antigen complexes on the
DC surface for cytotoxic T lymphocytes stimulation [25].
It has been mentioned that low-burst release of encapsu-
lated antigen is crucial for an efficient MHC class I
antigen presentation and CD8+ T cell activation [26].
Decreased immunoinhibitory cytokines IL-10 and IL-
4 or increased immunostimulatory cytokines IL-12 and
IFN-γ cytokines was detected in cells obtained from all
of three patients after PLGA-mediated antigen delivery.
The secretion level of IFN- γ was higher than that of
IL-4 or IL-12 than IL-10 in all three patients. Regarding
literature review and our results as well, it is clear that
in comparison to tumor lysate alone, PLGA-NP medi-
ated breast tumor antigen delivery to DCs did not re-
sult in significant differences in either IFN-γ or IL-4
production as well as immune response polarization,
but in the case of PLGA-NP mediated antigen delivery
when the tumor lysate is delivered via PLGA-NP lower
amounts of antigen is significantly required to elicit
same magnetitude of immune responses. This is very
important in the cases where the tumor antigen mass is
limited when the antigen scours is fine needle biopsies
or metastatic sites of tumor.
Therapeutic vaccination is given following the onset of
disease and aims to activate and maturate the DCs and
macrophages, and in turn, expansion of cell mediated
cytotoxicity which eventually leads to death of tumor
cells. Matured DCs secrete the T-cell differentiation fac-
tor, IL-12, which present antigens more effectively and
up-regulate co-stimulatory molecules as a result of
increased phenotypic stability and extended half-life of
MHC class I- and II molecules [27]. Once a cell-mediated
immune response is propagated, cytokines (IFN- γ and
Fig. 7 T cells proliferation responses induced by dendritic cells. Magnetic cell sorting (MACS)-enriched CD3+ T cells were stimulated with
autologous DCs pulsed with a DCs treated with tumor antigen pulsed nanoparticles fabricated using three different amounts (concentrations) of
PVA, b Comparison of DCs pulsed with nanoparticles containing tumor antigen with those pulsed with either tumor lysate or NPs alone, at a
ratios of 5:1, 10:1 and 20:1 for five days and proliferation rates were meassured by MTT assay. The triplicate proliferation indices from three
patients were averraged and expressed as mean ±S.D (n = 3) (P 0.05)
Fig. 8 Cytokines released by mature DCs in the supernatant of seventh day of DC culture. IL-12 and IL-10 production were measured
using commercially available ELISA kit. Triplicate data obtained from three patients were averaged and expressed as mean ± S.D (n = 3).
a cytokines produced by mature DCs, b IL-12:IL-10 ratio, (P ≤ 0.05) (*: indicates the statistical significance)
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TNF-α) and chemokines along with contact-mediated
cytotoxicity result in death of the tumor cells [28].
Although, in the most of the previous studies tumor
cell lines expressing the immunodominant peptides
have been used for encapsulation along with tailored
T-cell lines for certain specific epitopes, there is one
study in which the whole-tumor material from freshly
excised surgical specimens and freshly isolated T cells
had been used as it has been done in the present
study [21].
Unlike previous studies, no variations in cytokine profiles
among samples from three different patients have been ob-
served in the present study. NPs delivery resulted in a
greater immuno-stimulatory secretion of IFN-γ and ad-
versely lower immunoinhibitory secretion of IL-10 in all
three patients. NPs encapsulated with tumor lysate were
able to stimulate specific T cells to produce larger quantities
of Th1 and Th2-based cytokines including IFN- γ and IL-4,
respectively. The higher concentrations of IFN- γ and IL-12
were detected in NPs encapsulated tumor lysate compared
to tumor lysate and NPs alone. The results of this study
provide evidence of principle that the whole tumor lysates
can stimulate T cell-released cytokines, when delivered to
DC in a particulate form. Up-regulationin expression of
CD80, CD86, HLADR and CD83 markers and down-
regulation in expression of CD14surface marker showed
that the incubation of immature DCs with both NP
containing antigen and antigen alone would lead to the
phenotypic maturation and activation of DCs. Antigens or
pathogens and pathogen-associated molecules can
naturally induce DC maturation [29]. It has also been
reported that PLGA-MS-treated and, subsequently,
matured DCs display the same strong enhancement in
their capacity to stimulate naive autologousT helper cells
and secret the same amount of the cytokines, such as
IL-12, IL-10 and TNF.
Conclusions
PLGA-NPs are attractive vehicles for protein antigen de-
livery for an effective stimulation and maturation of
DCs, allowing not only an enhancement in antigen pro-
cessing and immunogenicity or improvement of antigen
stability, but also they improve the targeted delivery and
slow release of antigens. Matured and stimulated DCs
display the strong enhancement in their capacity to
stimulate naive autologous T helper cells and secret the
amount of the cytokines.
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